Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2024-10-01 Epub Date: 2024-06-20 DOI:10.1002/jpn3.12287
Holly Payton Shifman, Joanne Hatchett, Ruth-Anne Pai, Ricky Safer, Rachel Gomel, Mary Vyas, Michael Li, Jennifer C Lai, Sharad I Wadhwani
{"title":"Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.","authors":"Holly Payton Shifman, Joanne Hatchett, Ruth-Anne Pai, Ricky Safer, Rachel Gomel, Mary Vyas, Michael Li, Jennifer C Lai, Sharad I Wadhwani","doi":"10.1002/jpn3.12287","DOIUrl":null,"url":null,"abstract":"<p><p>This study analyzed qualitative and quantitative survey responses from 51 pediatric primary sclerosing cholangitis (PSC) patients and caregivers using the PSC Partners Patient Registry-Our Voices survey. The most common symptoms reported by children/caregivers include: fatigue (71%), abdominal pain (69%), anxiety (59%), appetite loss (51%), insomnia (49%), and pruritus (45%). When experiencing symptoms at their worst, over half of patients/caregivers reported limitations in physically demanding activities (67%), work/school duties (63%), social life activities (55%), and activities for fun or exercise (53%). Over half of patients/caregivers expressed willingness to participate in clinical trials, however none reported ever participating in trials for new or investigational PSC drugs. This study revealed a substantial patient/caregiver-reported symptom burden for children with PSC that impacts quality of life and limits access to clinical trials. Future efforts should focus on developing patient-centered clinical endpoints for PSC trials, increasing trial availability for pediatric PSC patients, and reducing logistical barriers to trial involvement.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"835-840"},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444895/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jpn3.12287","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

This study analyzed qualitative and quantitative survey responses from 51 pediatric primary sclerosing cholangitis (PSC) patients and caregivers using the PSC Partners Patient Registry-Our Voices survey. The most common symptoms reported by children/caregivers include: fatigue (71%), abdominal pain (69%), anxiety (59%), appetite loss (51%), insomnia (49%), and pruritus (45%). When experiencing symptoms at their worst, over half of patients/caregivers reported limitations in physically demanding activities (67%), work/school duties (63%), social life activities (55%), and activities for fun or exercise (53%). Over half of patients/caregivers expressed willingness to participate in clinical trials, however none reported ever participating in trials for new or investigational PSC drugs. This study revealed a substantial patient/caregiver-reported symptom burden for children with PSC that impacts quality of life and limits access to clinical trials. Future efforts should focus on developing patient-centered clinical endpoints for PSC trials, increasing trial availability for pediatric PSC patients, and reducing logistical barriers to trial involvement.

护理人员报告的小儿原发性硬化性胆管炎的症状负担和治疗目标偏好。
本研究通过 "PSC 合作伙伴患者登记--我们的声音 "调查对 51 名儿科原发性硬化性胆管炎(PSC)患者和护理人员的定性和定量调查回复进行了分析。儿童/护理人员报告的最常见症状包括:疲劳(71%)、腹痛(69%)、焦虑(59%)、食欲不振(51%)、失眠(49%)和瘙痒(45%)。当症状最严重时,超过半数的患者/护理者表示体力活动(67%)、工作/学业(63%)、社交活动(55%)以及娱乐或锻炼活动(53%)受到限制。超过半数的患者/照护者表示愿意参加临床试验,但没有人表示曾参加过新药或研究性 PSC 药物的试验。这项研究显示,患者/护理者报告的 PSC 儿童症状负担很重,影响了他们的生活质量,并限制了他们参与临床试验的机会。未来的工作重点应该是为 PSC 试验开发以患者为中心的临床终点,增加儿科 PSC 患者的试验机会,并减少参与试验的后勤障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信